Loading
Life sciences · Journal article
Acs Omega · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Diosmetin (Dio) is a natural flavonoid with broad-spectrum anticancer activity against various malignancies through mechanisms involving cell cycle arrest, apoptosis induction, metastasis inhibition, and modulation of oncogenic signaling pathways such as STAT3/c-Myc and PI3K/AKT/mTOR; with the exception of CDK2, which has been proposed as a direct target in esophageal squamous cell carcinoma, no other direct molecular targets of diosmetin have been identified to date. It also exhibits synergistic efficacy with reduced toxicity when combined with radiotherapy or chemotherapy. However, clinical translation is severely hampered by poor water solubility, low bioavailability, and unidentified direct molecular targets. Structural modifications (esterification, etherification, phosphorylation) and advanced drug delivery systems (SMEDDS, targeted liposomes, composite nanoparticles) offer promising strategies to overcome these limitations. This review provides an integrated framework covering the complete chain from extraction and chemical derivatization to formulation strategies and anticancer mechanisms, with critical analysis of current translational bottlenecks, particularly the disconnect between in vitro and in vivo findings. By integrating chemical optimization with pharmacological mechanisms, this review aims to provide a theoretical foundation to inform and guide future preclinical and translational research on Dio as a potential adjunct to existing cancer therapies. While some of these strategies have been validated in cancer models, others have been demonstrated in noncancer settings and await translation to oncology.